135 related articles for article (PubMed ID: 37440269)
1. Challenging T-ALL to IL-7Rp dual inhibition.
Fries C; Hermiston ML
Blood; 2023 Jul; 142(2):124-126. PubMed ID: 37440269
[No Abstract] [Full Text] [Related]
2. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.
Courtois L; Cabannes-Hamy A; Kim R; Delecourt M; Pinton A; Charbonnier G; Feroul M; Smith C; Tueur G; Pivert C; Balducci E; Simonin M; Angel LH; Spicuglia S; Boissel N; Andrieu GP; Asnafi V; Rousselot P; Lhermitte L
Blood; 2023 Jul; 142(2):158-171. PubMed ID: 37023368
[TBL] [Abstract][Full Text] [Related]
3. Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
Cramer SD; Hixon JA; Andrews C; Porter RJ; Rodrigues GOL; Wu X; Back T; Czarra K; Michael H; Cam M; Chen J; Esposito D; Senkevitch E; Negi V; Aplan PD; Li W; Durum SK
Leukemia; 2018 Aug; 32(8):1795-1882. PubMed ID: 29535426
[No Abstract] [Full Text] [Related]
4. A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
Akkapeddi P; Fragoso R; Hixon JA; Ramalho AS; Oliveira ML; Carvalho T; Gloger A; Matasci M; Corzana F; Durum SK; Neri D; Bernardes GJL; Barata JT
Leukemia; 2019 Sep; 33(9):2155-2168. PubMed ID: 30850736
[TBL] [Abstract][Full Text] [Related]
5. [Mutation of IL-7R in Adult Patients with T-cell Acute Lymphoblastic Leukemia and Its Clinical Significance].
Xiao LC; Li M; Ge Z; Gu Y; Zhou XL; Guo X; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1014-8. PubMed ID: 27531766
[TBL] [Abstract][Full Text] [Related]
6. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
7. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
8. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2013 May; 53(2):211-22. PubMed ID: 23234870
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
10. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias.
Silva A; Laranjeira AB; Martins LR; Cardoso BA; Demengeot J; Yunes JA; Seddon B; Barata JT
Cancer Res; 2011 Jul; 71(14):4780-9. PubMed ID: 21593192
[TBL] [Abstract][Full Text] [Related]
11. New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.
Hixon JA; Andrews C; Kashi L; Kohnhorst CL; Senkevitch E; Czarra K; Barata JT; Li W; Schneider JP; Walsh STR; Durum SK
Leukemia; 2020 Jan; 34(1):35-49. PubMed ID: 31439943
[TBL] [Abstract][Full Text] [Related]
12. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
13. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C; Schwab C; Broux M; Geerdens E; Degryse S; Demeyer S; Lahortiga I; Elliott A; Chilton L; La Starza R; Mecucci C; Vandenberghe P; Goulden N; Vora A; Moorman AV; Soulier J; Harrison CJ; Clappier E; Cools J
Haematologica; 2015 Oct; 100(10):1301-10. PubMed ID: 26206799
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 priming chemotherapy: a strategy to improve the remission of refractory/relapsed T cell acute lymphoblastic leukemia.
Zhang C; Zhang X; Chen XH
Med Hypotheses; 2013 Nov; 81(5):878-80. PubMed ID: 24074835
[TBL] [Abstract][Full Text] [Related]
16. Notch1 and IL-7 receptor signalling in early T-cell development and leukaemia.
González-García S; García-Peydró M; Alcain J; Toribio ML
Curr Top Microbiol Immunol; 2012; 360():47-73. PubMed ID: 22695916
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.
Silva A; Almeida ARM; Cachucho A; Neto JL; Demeyer S; de Matos M; Hogan T; Li Y; Meijerink J; Cools J; Grosso AR; Seddon B; Barata JT
Blood; 2021 Sep; 138(12):1040-1052. PubMed ID: 33970999
[TBL] [Abstract][Full Text] [Related]
18. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T
Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
20. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
